No Meaningful Opioid Abuse Liability of REL-1017 (esmethadone; d-methadone), a Rapid-Acting Antidepressant in Clinical Development: A Human Abuse Potential Study

Henningfield JE, Apseloff G, Gorodetzky C, Pappagallo M, Shram M, de Martin S, Fant RV, Vocci F, Sapienza F, Kosten T, Huston J, Buchhalter AR, Ashworth J, Lanier R, Folli F, Traversa S, Inturrisi CE, Manfredi PL.

We aimed to assess the human abuse potential (HAP) of REL-1017 in a single-dose, randomized, double-blind, double dummy, active- and placebo-controlled, 5-way crossover study in experienced recreational drug users.

Presented at the American College of Neuropsychopharmacology 60th Annual Meeting, December 5–8, 2021.